Toxys is a biotech company and service laboratory that offers a broad spectrum of innovative in vitro solutions with expertise in genotoxicity, developmental and mechanistic toxicity screening.
Toxys aims to bring information to our customers that is essential to make decisions on which compounds to progress in drug/product development.
Toxys was founded in 2014 as a spin-off from the Leiden University Medical Center and has its state-of-the-art laboratory facilities located at the Leiden BioScience Park. The company is headquartered in Leiden, South Holland, Netherlands.
Toxys works together with customers from different industries ranging from pharmaceutical companies to chemical and consumer-goods companies and from large size companies to small start-ups.
Toxys is devoted to offer their unique assays such as ToxTracker®, ToxTrackerPlus® and Reprotracker® together with the conventional genotoxicity assays as tailored service to our customers, combined with the responsiveness and flexibility found only in dedicated companies.
Toxys has raised €2M in a Seed round on Mar 12, 2020. The investment is backed by KIKK Capital, InnovationQuarter, Zeeland Investment fund, Toxys management and Rabobank.